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Gestational trophoblastic neoplasia (GTN) describes a heterogeneous group of interrelated lesions that arise from abnormal
proliferationofplacentaltrophoblasts.GTNlesionsarehistologicallydistinct,malignantlesionsthatincludeinvasivehydatidiform
mole, choriocarcinoma, placental site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT). GTN tumors
are generally highly responsive to chemotherapy. Early stage GTN disease is often cured with single-agent chemotherapy. In
contrast, advanced stage disease requires multiagent combination chemotherapeutic regimens to achieve a cure. Various adjuvant
surgical procedures can be helpful to treat women with GTN. Patients require careful followup after completing treatment and
recurrent disease should be aggressively managed. Women with a history of GTN are at increased risk of subsequent GTN, hence
future pregnancies require careful monitoring to ensure normal gestational development. This article will review the workup,
management and followup of women with all stages of GTN as well as with recurrent disease.
1.Introduction
Gestational trophoblastic neoplasia (GTN) are malignant
lesions that arise from abnormal proliferation of placental
trophoblast. The pathologic conditions that make up this
entity include invasive partial and complete hydatidiform
mole, choriocarcinoma, placental site trophoblastic tumor
(PSTT), and epithelioid trophoblastic tumor (ETT). GTN
often arises after molar pregnancies but can also occur after
any gestation including miscarriages and term pregnancies.
In the United States, hydatidiform moles are observed in
approximately 1/600 therapeutic abortions and 1/1000–
2000 pregnancies [1, 2]. Fortunately, these malignancies are
highly susceptible to chemotherapy and it is often possible
to achieve cure while preserving the woman’s reproduc-
tive function [3–7]. This article will review the current
chemotherapeutic management of patients with GTN.
2. Workup of Patients withGTN
Women newly diagnosed with GTN require a thorough eval-
uation of the extent of their disease such that the appropriate
treatment can be selected. This evaluation includes a history
and physical exam, serum quantitative hCG level, a complete
blood count, and hepatic and renal function tests.
A pelvic ultrasound is often useful to detect the extent
of uterine involvement and may identify patients who are
at risk for uterine perforation or who would beneﬁt from
a hysterectomy to reduce tumor burden [7, 8]. A chest X-
ray should be obtained to evaluate lung metastasis. If this
is negative, a chest computed tomography (CT) scan may
be performed since it may detect micrometastases in 40%
of patients with a negative chest X-ray [9, 10]. Additional
imaging can be omitted in asymptomatic patients with a
negative chest CT given that distant metastases are unlikely
in the absence of lung metastases. Conversely, abdominal
and brain imaging are an essential part of the workup in
patients with metastases to the vagina or to the lungs and
in patients with a histological diagnosis of choriocarcinoma.
Furthermore, an elevated cerebral spinal ﬂuid/plasma hCG
ratio may suggest cerebral involvement [11, 12]. Additional
imaging, such as 18-ﬂuorodeoxyglucose positron emission
tomography (FDG-PET), may be useful to accurately outline
sites of metabolically active or viable metastases and help2 Chemotherapy Research and Practice
Table 1: FIGO anatomic staging for gestational trophoblastic neoplasia (GTN).
Stage I Disease conﬁned to the uterus
Stage II GTN extends outside of the uterus, but is limited to the genital structures (adnexa, vagina, broad ligament)
Stage III GTN extends to the lungs, with or without known genital tract involvement
Stage IV All other metastatic sites
FIGO: International Federation of Gynecology and Obstetrics.
Table 2: FIGO prognostic scoring system∗.
Scores 0 1 2 4
Age (years) ≤39 ≥40 — —
Antecedent pregnancy Mole Abortion Term
Interval from index pregnancy (months) <4 4–6 7–12 >12
Pretreatment serum hCG (IU/liter) <1000 <10,000 <100,000 >100,000
Largest tumor size (incl, uterus) — 3-4cm >5cm —
Site of metastases Lung Spleen/kidney GI Liver/brain
Number of metastases — 1–4 5–8 >8
Previous failed chemotherapy Single drug 2 or more drugs
∗Format for reporting to FIGO Annual Report: in order to stage and allot a risk factor score, a patient’s diagnosis is allocated to a stage as represented by a
roman numeral I, II, III, and IV. This is then separated by a colon from the sum of all the actual risk factor scores, which is expressed in Arabic numerals (e.g.,
stage II:4, stage IV:9). This stage and score will be allotted for each patient.
FIGO: International Federation of Gynecology and Obstetrics.
determine the potential for tumor resectability [13]. If a
patient has a drug-resistant disease, a PET scan can help
determine if a persistent radiographic ﬁnding has viable,
active tumor.
3. GTN after a Molar Gestation
The risk of developing GTN after a complete hydatidiform
mole (CHM) and a partial hydatidiform mole (PHM) is 15–
20% and 1–4%, respectively [14].
In accordance with the International Federation of
Gynecology and Obstetrics (FIGO), GTN is diagnosed after
a molar gestation if any of the following is observed [15]:
(1) four values or more of hCG plateau over at least three
weeks (days 1, 7, 14, and 21),
(2) a rise in hCG of 10% or greater for three or more
values over at least two weeks (days 1, 7, and 14),
(3) the presence of histologic choriocarcinoma,
(4) persistence of hCG six months after molar evacua-
tion.
CHM is well recognized to have the potential for local
invasionanddistantspread.FollowingevacuationofaCHM,
local uterine invasion occurs in approximately 15% and
metastases is observed in 4% of patients [14]. Interestingly,
patients with CHM who present with excessive uterine
size and markedly elevated hCG levels (>100,000mIU/mL)
develop GTN in 40–50% of cases and are considered
high risk [14]. Postmolar, locally-invasive GTN commonly
presents with irregular vaginal bleeding. In certain cases, the
invasive tumor may erode into the uterine vessels leading to
signiﬁcantvaginalhemorrhage.Inotherinstances,itcanper-
forate through the myometrium leading to intraperitoneal
hemorrhage. In addition, a necrotic intrauterine tumor may
s e r v ea saf o c u sf o ri n f e c t i o n .
4.FIGOStagingand PrognosticScore
When reporting GTN data, it is useful to use both the FIGO
anatomic staging system and prognostic scoring system [15]
(Tables 1 and 2). A FIGO score of 6 or less indicates low-
risk GTN whereas a score of 7 or more identiﬁes high-risk
disease. High-risk GTN has increased resistance to single-
agent chemotherapeutics, increased risk of recurrence, and
generally requires combination chemotherapy to achieve
remission.
5.MetastaticGTN
Metastatic GTN occurs in 4% of patients after evacuation
of CHM and infrequently after other pregnancies [14]. The
most common metastatic sites are the lung (80%), vagina
(30%), brain (10%), and liver (10%) [16]. Trophoblastic
tumors are perfused by fragile vessels and, as a result,
metastases are often hemorrhagic. Biopsy of metastases is
neither necessary nor recommended due to the risk of
hemorrhage. Patients may present with signs and symptoms
of bleeding from metastases such as hemoptysis, intraperi-
toneal bleeding, or acute neurologic deﬁcits. Cerebral and
hepatic metastases are uncommon unless there is concurrent
involvement of the lungs and/or vagina.Chemotherapy Research and Practice 3
Patients with pulmonary metastases commonly have
asymptomatic lesions on chest radiography or they may
present with dyspnea, chest pain, cough, or hemoptysis.
Trophoblastic emboli may cause pulmonary arterial occlu-
sion and lead to rightheart strain and pulmonary hyper-
tension [17]. This may lead to a false diagnosis of primary
pulmonary disease especially if the antecedent pregnancy
is remote and the gynecologic symptoms are minimal or
absent. It is, therefore, imperative to consider GTN in any
woman in the reproductive age group with unexplained
systemic or pulmonary symptoms. Interestingly, 40% of
patients with presumed nonmetastatic disease have occult
pulmonary nodules on CT scan [9, 10]. Given that the FIGO
staging system includes ﬁndings on CXR, but not CT scan,
these patients will be classiﬁed as stage I; however, their
management might be inﬂuenced by the CT ﬁndings.
The vagina is the second most common site of metastasis
and is involved in 30% of metastatic cases. Patients often
present with irregular vaginal bleeding or purulent vaginal
discharge.Vaginalexaminationoftenrevealsvascularlesions,
most commonly located in the suburethral region or at the
vaginal fornices. Given the high vascularity of these lesions,
they should not be biopsied since this can lead to signiﬁcant
hemorrhage.
A small portion of women with GTN will have cere-
bral metastases. Cerebral involvement can cause increased
intracranial pressure and intracerebral bleeding, which often
leads to neurological symptoms. As such, most women with
brain involvement have clear neurological symptoms includ-
ing nausea, vomiting, headache, seizures, slurred speech,
visual disturbances, or hemiparesis [18–22]. Neurological
symptoms were observed in patients with brain metastasis
in 20 of 23 patients (87%) by Bakri et al., 66 of 69 patients
(96%) by Athanassiou et al., and in all 34 patients (100%) by
Liu et al. [19, 21, 22].
Infrequently, women with GTN will have liver metas-
tases. The majority of these patients will have disease
involving other organ systems such as the lungs, vagina, and
other distant sites. Interestingly, these patients uncommonly
present with symptoms related to hepatic involvement but
rather with symptoms related to involvement of the other
sites. Bakri et al. noted that only 5 of 19 patients (26%) with
livermetastasespresentedwithliver-relatedcomplaints,such
asjaundice,intraabdominalbleeding,orepigastricpain[23].
6 .T r eatm e n to fL o w - R is kGT N
Patients with stage I and low-risk stage II and III GTN
(FIGO prognostic score of ≤6) generally respond well to
single-agent chemotherapy. A repeat dilation and curettage
is usually not indicated as it may increase risks of bleeding
and infection without decreasing the need of adjuvant
chemotherapy. The most commonly used agents for low-risk
GTN are sequential methotrexate (MTX) and actinomycin-
D (ACT-D). At the New England Trophoblastic Disease
Center (NETDC), we use MTX as a ﬁrst-line agent given its
lower side eﬀect proﬁle as compared to ACT-D [24]. MTX
causes less nausea, less vomiting, and no alopecia. We believe
that ACT-D can be used as a ﬁrst-line agent in patients with
hepaticdysfunctionorwhohaveaknownadversereactionto
MTX.
Fortunately, single-agent chemotherapy can be very
eﬀective in treating low-risk GTN. At our center, 632
women with low-risk GTN were treated with single-agent
chemotherapy between 1965 and 2006. Complete remission
was achieved in 419 of 502 patients (83.5%) with stage I
GTN, 16 of 20 patients (80%) with low-risk, stage II disease,
and 90 of 110 patients (81.8%) with low-risk, stage III GTN.
After administering the ﬁrst course of chemotherapy, it is
our practice to closely monitor patients’ hCG level. Further
chemotherapy is given if the hCG value fails to decline by
1 log within 18 days of the ﬁrst treatment, if the hCG level
plateaus for more than 3 consecutive weekly values, or if the
hCG level begins to rise.
Over the past several decades, multiple treatment pro-
tocols were eﬀectively used in treating low-risk GTN [25–
33]. Nonetheless, there has never been a trial that compared
the eﬀectiveness of all the regimens. At the NETDC, we
administer MTX in an eight-day treatment regimen consist-
ing of four administrations of MTX given at 1mg/kg every
other day with folinic acid 0.1mg/kg given on intervening
days. When we compared this protocol to one where patients
received100mg/m2 intravenous(IV)MTXbolusfollowedby
200mg/m2 IVMTXinfusedover12hoursfollowedbyfolinic
acid, the eight-day regimen was associated with a higher
remission rate in patients with low-risk GTN [34].
An important phase III randomized trial examining
MTX and ACT-D in the treatment of low-risk GTN was
published by the Gynecologic Oncology Group (GOG) in
2011 [35]. Two hundred sixteen patients were randomized
to receive either biweekly ACT-D 1.25mg/m2 IV or weekly
MTX 30mg/m2 intramuscularly (IM). The remission rate
was 58% in the MTX arm and 73% in the ACT-D arm.
These results suggest that ACT-D is superior to the weekly
MTX regimen in treating low-risk GTN. However, before
recommending pulse ACT-D as the primary modality in
the treatment of patients with low-risk GTN it is important
to be aware of the potential for signiﬁcant toxicity of this
regimen as compared to those with MTX. Furthermore, all
patients with low-risk disease in the Osborne series ulti-
matelyachievedremissionregardlessoftheirinitialresponse.
Therefore, in order to reach deﬁnitive conclusions regarding
the true comparative eﬀectiveness of these agents, it would
be prudent to compare the biweekly ACT-D regimen to the
more commonly used 5-day or 8-day MTX regimens which
oﬀer a high initial remission rate with minimal toxicity.
In women who no longer desire fertility, a hysterectomy
may be considered in stage I disease to decrease exposure to
multiple doses of chemotherapeutic agents. In this treatment
strategy, the patient receives one course of single-agent
chemotherapy at the time of surgery. This is imperative
to treat occult metastases that may be present at the time
of surgery, to reduce the likelihood of disseminating viable
tumor cells during surgery, and to maintain a cytotoxic
level of chemotherapy in the blood and tissues in case
viable tumor cells are disseminated during surgery. At our
center, 32 patients with stage I GTN were treated with4 Chemotherapy Research and Practice
ahysterectomyand perioperative chemotherapy. None of the
patients experienced intraoperative or perioperative com-
plications, none required additional adjuvant therapy, and
all patients achieved complete remission. This suggests that
administration of chemotherapy at the time of hysterectomy
is a safe and eﬀective treatment strategy for selected women
with stage I GTN.
Despite the excellent eﬀectiveness of MTX and ACT-D in
treating low-risk GTN, some patients experience resistance
to both agents. Recent data from Charing Cross Hospital
indicate that patients with a low-risk FIGO score but with
an hCG value exceeding 100,000mIU/mL frequently require
combination chemotherapy [36]. These women are often
treated with MAC (MTX, ACT-D, and Cyclophosphamide)
or EMACO (Etoposide, MTX, ACT-D, Cyclophosphamide,
andVincristine).MACispreferredastheinitialcombination
chemotherapy regimen since etoposide, which is a compo-
nent of EMACO, is associated with an increased risk for
secondary malignancies. Studies have shown that patients
treated with more than 2g/m2 of etoposide, had a relative
risk of 16.6 for developing leukemia, 5.8 for breast cancer,
4.6 for colon cancer, and 3.4 for melanoma [37].
In addition to medical therapy, surgical management
may be useful in cases where GTN continues to be resistant
to combination chemotherapy. Preoperative imaging studies
such as ultrasound, MRI, arteriography, and positron emis-
sion tomography (PET) scans may be helpful in identifying
the site of residual tumor and can, therefore, facilitate surgi-
cal planning [13, 38] .I fal a r g et u m o rv o l u m ei si d e n t i ﬁ e d
within the uterus, a hysterectomy may be performed to
remove the focus of drug resistance. If the woman desires
to retain her fertility, local uterine resection of the tumor
mass can be attempted. This management option should
be reserved for carefully selected patients. Women should
be counseled about the potential future obstetrical risks
associated with this procedure, including uterine rupture
[39]. Two patients at the NETDC were successfully treated in
this manner, and one patient went on to carry a pregnancy
to term and was delivered by cesarean section. Allison et al.
reported a patient with persistent GTN who underwent
fertility-sparing surgery and went on to have a successful
pregnancy [39]. Similarly, Behtash et al. described a patient
with choriocarcinoma and a perforated uterus who was
treatedwithlocalizeduterineresectionandsubsequentlyhad
an uncomplicated pregnancy [40].
Table 3 summarizestheNETDC’sprotocolfortreatingstage
IG T N ,a n dTable 4 s u m m a r i z e st h eN E T D C ’ sp r o t o c o lf o r
treating low-risk, stage II and III disease.
7. Treatment of High-Risk, Stage II and III GTN
Patients with stage II or III GTN and an FIGO prognostic
score ≥7 have a high-risk disease and are unlikely to be cured
with single-agent therapy. Therefore, they should be treated
with combination chemotherapy [41]. Importantly, MAC is
inadequate as primary treatment for high-risk, metastatic
GTN as it induces remission in only half the patients [42–
44]. At the NETDC, EMACO is the ﬁrst-line regimen used
Table 3: Treatment protocols for stage I gestational trophoblastic
neoplasia (New England Trophoblastic Disease Center).
Initial Sequential MTX/ACT-D
Hysterectomy (with adjunctive single-agent
chemotherapy)
Resistant to
both single-
agents
MAC
EMACO, if MAC fails
Hysterectomy (with adjunctive multiagent
chemotherapy)
Local uterine resection (for localized lesion, to
preserve, fertility)
Followup 12 consecutive months of normal hCG levels
Contraception mandatory
ACT-D: actinomycin D; EMACO: etoposide, methotrexate, actinomycin
D, cytoxan, oncovin; MAC: methotrexate, actinomycin D, cytoxan; MTX:
methotrexate.
to treat high-risk GTN since it has the best eﬀectiveness-
to-toxicity ratio. At our center, combination chemotherapy
induced complete remission in 6 of 6 patients (100%) with
high-risk stage II GTN and in 36 of 37 patients (97.3%)
with high-risk stage III GTN. At other centers, Bower et al.
and Bolis et al. reported that EMACO induced remission in
86% and 76% of patients with high-risk metastatic GTN,
respectively [45, 46].
Although EMACO is the most commonly used com-
bination chemotherapy, other regimens have been used
in the management of high-risk GTN. In a retrospective
analysis of four chemotherapeutic regimens, Kim et al.
compared the eﬀectiveness of MFA (MTX, folinic acid,
ACT-D), MAC, CHAMOCA (cyclophosphamide, hydrox-
ycarbamide, doxorubicin, ACT-D, MTX, melphalan, and
vincristine) and EMACO. They reported remission rates of
63%, 68%, 71%, and 91%, respectively [47]. These results
support EMACO’s eﬀectiveness as primary therapy for
patients with high-risk disease. Combination chemotherapy
is often administered at two- to three-week intervals and
timely administration is essential. Unnecessary treatment
delays and dose reductions should be avoided as they may
lead to tumor resistance and treatment failure. Patients
receivingcombinationchemotherapyshouldhaveserialhCG
measurements. After the ﬁrst undetectable hCG level, 2 to 4
additional chemotherapy courses are administered to reduce
the risk of relapse [48–50].
Patients with disease resistant to EMACO can be
treatedusingEMAEP—aregimenthatsubstitutescyclophos-
phamide and vincristine on day 8 with cisplatin and
etoposide [45, 51]. In 21 patients with disease resistant to
EMACO, 16 (76%) were successfully treated with EMAEP,
either alone or with surgery [45].
Other regimens have also been eﬀective in treating high-
risk refractory GTN including BEP (bleomycin, etoposide,
cisplatin), ICE (ifosfamide, carboplatin, etoposide), and
VIP (etoposide, ifosfamide, cisplatin) [52–55]. In a case
report, Willemse et al. describe a 53-year-old woman with
metastatic GTN who did not respond to initial treatmentChemotherapy Research and Practice 5
with a combination of MTX, ACT-D, and chlorambucil
and who was subsequently treated with BEP [52]. Complete
remission was achieved; however, the patient suﬀered from
moderate, transient bleomycin pneumonitis.
Piamsomboon et al. reported a patient who developed
brain metastasis while on EMACO. The patient was suc-
cessfully treated with a low-dose salvage ICE regimen [53].
Furthermore,aphaseI-IItrialwasconductedbyLotzetal.to
assess the toxicity and eﬃcacy of the ICE regimen combined
with autologous bone marrow transplantation in germ cell
tumors and metastatic GTN [54]. Thirty-nine patients were
studied, including 5 with drug-resistant GTN. The overall
response rate was 46%, including a complete response rate of
35%.Amongthe5patientswithGTN,thecompleteresponse
rate was 40% (2/5) and there were no partial responses.
Importantly, several patients reported serious side eﬀects,
which were primarily renal toxicity and enterocolitis. It is
not clear how many patients with GTN suﬀered from major
side eﬀects given that the toxicity incidence was not stratiﬁed
accordingthepatient’sdiagnosis.Inaddition,7of39patients
(18%) died of therapy-related causes, including one patient
with GTN who developed refractory thrombocytopenia and
died of cerebral hemorrhage. Hence, although the ICE
regimen appears to overcome drug resistance in highly
refractory germ cell tumors and GTN, it was associated with
signiﬁcant morbidity and mortality [54].
To compare various combination chemotherapy regi-
mens, Lurain and Nejad evaluated 26 patients with relapsed
GTN [55]. Sixteen patients were initially treated with
MTX or ACT-D and 10 with EMACO. Of the 16 patients
who resisted initial MTX or ACT-D therapy, 10 (63%)
achievedcompleteremissionaftersecondarytherapyconsist-
ing mainly of platinum and etoposide combinations. Eight
patientsweretreatedwithBEP,1withVIP,and1withICE.Of
the 10 patients with resistance to EMACO, 9 (90%) achieved
complete remission with second-line chemotherapy. Three
patients were treated with EMAEP and 6 with BEP. The
authors, therefore, concluded that patients with persistent or
recurrent GTN should be treated with drug combinations
employing both a platinum agent and etoposide with or
without bleomycin or ifosfamide [55].
In some women, chemotherapy alone may not suc-
cessfully treat GTN, and they may beneﬁt from adjuvant
surgicalexcision ofthechemoresistanttumor[7].Clarketal.
reported that 25 of 33 women (76%) with chemoresistant
uterine tumor achieved complete remission with hysterec-
tomy [56]. An additional beneﬁt to surgical treatment is that
it may reduce tumor mass and may decrease the dose and
length of administration of chemotherapy. This was high-
lighted in a report by Hammond et al. stating that patients
who underwent hysterectomy had shorter hospitalization
and a briefer chemotherapy treatment course [7].
An interesting procedure in the management of stage
III GTN is thoracotomy, which has a limited yet important
role in the management of lung metastases. Thoracotomy
can be useful to establish the diagnosis of GTN if the
diagnosis cannot be clariﬁed using less invasive measures.
In addition, in patients with persistent, viable pulmonary
nodules that are resistant to chemotherapy, pulmonary
Table 4: Treatment protocol for stages II and III gestational tro-
phoblastic neoplasia (New England Trophoblastic Disease center).
Low risk
Initial therapy Sequential MTX/ACT-D
Resistant therapy MAC or EMA/CO
Surgery, as indicated
High risk
Initial therapy EMACO
Resistant therapy
EMAEP
VBP
Surgery, as indicated
Followup
12 consecutive months of undetectable
hCG levels
Contraception for 12 months
ACT-D: actinomycin D; EMACO: etoposide, methotrexate, actinomycin D,
cytoxan, oncovin; EMAEP: etoposide, methotrexate, actinomycin D, carbo-
platin; MAC: methotrexate, actinomycin D, cytoxan; MTX: methotrexate;
VBP: vinblastine, bleomyCin, carboplatin.
resection may be curative [57]. Tomoda et al. reported
on 19 patients with chemoresistant GTN that were treated
with adjuvant thoracotomy [58]. Based on their experience,
they proposed the following criteria to predict successful
pulmonaryresection:(a)patientisagoodsurgicalcandidate,
(b) primary malignancy is controlled, (c) no evidence of
other metastatic sites, (d) pulmonary metastasis is limited
to one lung, and (e) hCG level is <1,000mIU/mL. In their
series, complete remission was achieved in 14 of 15 patients
(93%) who met all ﬁve criteria but in zero of 4 patients
(0%) who met only 4 or less of the criteria [58]. Similarly,
Fleming et al. reported that ten of eleven carefully selected
patients (90.9%) with drug-resistant pulmonary metastases
achieved remission following resection of the pulmonary
tumor [59]. Notably, an undetectable hCG level within
2 weeks of resection of a solitary pulmonary nodule is
highly predictive of a favorable outcome [60–64]. Although
pulmonary resection can be useful in selected cases, it is
important to note that thoracotomy is seldom necessary
and that most lung lesions can be successfully treated with
chemotherapy.
Table 4 summarizes the NETDC’s protocol for managing
high-risk, stage II and III GTN.
8. Treatment of Stage IV GTN
Strikingly, prior to 1975, survival of patients with stage
IV GTN at the NETDC was only 30%. Since then, the
survival of these women has risen dramatically to 80%
largely due to the introduction of early, concentrated,
multiagent chemotherapy. Hence, all patients with stage
IV disease at the NETDC are now treated with primary,
intensive, combination chemotherapy. The most common
combination chemotherapy we use to treat stage IV disease
is EMACO. Frequently, radiation treatment and surgical
interventionsarealsousedasadjuvanttherapyinthissetting.6 Chemotherapy Research and Practice
Women with cerebral metastases may pose speciﬁc
treatment challenges. The ﬁrst modiﬁcation to the EMACO
regimen in these patients is to increase the MTX dose on
day 1 to 1gm/m2 to ensure adequate coverage of brain
tissue [65, 66]. If resistance to EMACO is encountered,
EMAEP can be substituted eﬀectively. The use of adjuvant
brain irradiation is controversial. Yordan et al. reported
that mortality due to central nervous system involvement
was 44% (11 of 25) in patients treated with chemotherapy
alone whereas the mortality was zero in 18 patients treated
with chemotherapy and brain irradiation [67]. In contrast,
data from the Charing Cross Hospital reported that 30 of
35 patients (86%) with cerebral lesions achieved sustained
remission with intensive combination chemotherapy, which
included high-dose intravenous and intrathecal MTX, with-
out brain irradiation [65]. At the NETDC, we institute
adjuvant radiation therapy in all patients with cerebral
metastases. In addition, peripheral, solitary cerebral lesions
may be amenable to surgical resection [68]. Evans et al.
reported complete remission in 3 of 4 patients (75%) who
underwent craniotomy to relieve intracranial pressure, and
in 2 of 3 patients (66%) undergoing craniotomy for resec-
tion of chemoresistant tumor [68]. Similarly, Athanassiou
et al. reported that 4 of 5 patients (80%) undergoing
craniotomy for acute intracranial complications were ulti-
mately cured [21]. Importantly, the majority of patients
with treated cerebral metastases have no residual neurologic
deﬁcits.
Women with stage IV GTN with hepatic involvement
are often successfully treated with chemotherapy alone as
described by Wong et al. and Bakri et al., where 9 of 10
patients (90%) and 5 of 8 patients (62.5%), respectively,
achieved complete remission with primary intensive combi-
nation chemotherapy [23, 69].
Table 5 outlinestheNETDCprotocolformanagingstageIV
GTN.
9 .T r eatm e n to fP S TTan dETT
While hysterectomy is reserved for selected patients with
GTN, it should be considered as a ﬁrst-line treatment
strategy in women with stage I PSTT and ETT given that
these are relatively chemoresistant neoplasms. Women with
stage I PSTT or ETT are often eﬀectively treated with surgery
alone. Patients with metastatic PSTT may still achieve
remission with intensive combination chemotherapy after
surgical intervention, particularly when they are diagnosed
within 4 years of the antecedent pregnancy [70, 71]. ETT is
the rarest variety of GTN, hence there is limited data on the
optimal chemotherapy to treat patients with advanced-stage
disease [72].
10. Management of Complications from GTN
Women with GTN may present with complications related
to their disease and this may necessitate urgent management
including surgical interventions. Not infrequently, hysterec-
Table 5: Treatment protocol for stage IV gestational trophoblastic
neoplasia (New England Trophoblastic Disease Center).
Initial
EMACO
With brain metastases:
Radiation
Craniotomy for peripheral lesions
With liver metastases:
Embolization
Resection to manage complications
Resistant
Salvage chemotherapy:
EMAEP
VBP
Experimental protocols
Surgery, as indicated
Hepatic artery infusion or embolization, as indicated
Followup
Weekly hCG levels until undetectable for 3 weeks,
then monthly for 24 months
Contraception for 24 months
EMACO: etoposide, methotrexate, actinomycin D, cytoxan, oncovin;
EMAEP: etoposide. methotrexate, actinomycin D, carboplatin; VBP: vin-
blastine, bleomycin, carboplatin.
tomy may become necessary to control profuse uterine
hemorrhage or to remove an infected tumor focus [54].
In a retrospective study by Cagayan and Magallanes, 134
womeninthePhilippineswithGTNwerestudied[73].Inter-
estingly, 13 of 134 patients (9%) required a hysterectomy
for profuse vaginal bleeding, whereas 31 of 134 patients
(24%) underwent urgent hysterectomy for uterine rupture.
In patients who are hemodynamically stable, angiographic
uterine embolization can be eﬀective in the management of
uterine bleeding, especially in women who wish to retain
their fertility [74].
Vaginal metastases are often highly vascular and friable
and may bleed profusely. Yingna et al. reported that 18
of 51 patients (35.3%) with vaginal metastases presented
with vaginal hemorrhage [75]. Bleeding is often controlled
by packing the vagina. However, other modalities may
become necessary such as wide local excision of the lesions
or angiographic embolization of the hypogastric vessels.
Yingna et al. reported that vaginal bleeding was successfully
controlled with vaginal packing in 16 of 18 patients (88%)
and with angiographic embolization in the remaining 2
patients [75].
The management of complications from hepatic metas-
tases can be particularly challenging in patients with
advanced GTN. In rare instances, hepatic resection may be
required to control bleeding. Grumbine et al. reported on
the use of selective hepatic arterial occlusion and concurrent
combination chemotherapy in a patient with bleeding liver
metastases who ultimately attained complete remission
[76].Chemotherapy Research and Practice 7
11. Followup of Patients with GTN
All patients with GTN should be followed with weekly
serum quantitative hCG levels until normal for 3 consecutive
weeks, then monthly for 12 months. The monthly followup
period is extended to 24 months in patients with stage
IV disease given the increased risk of late recurrence in
this patient population. It is important to note that GTN
often generates fragmented or degraded hCG molecules.
As such, trophoblastic disease samples may contain high
proportions of free β-hCG, nicked hCG, as well as β-
core fragments [77, 78]. Hence, it is imperative to use
an hCG assay that detects hCG metabolites and frag-
ments when monitoring patients with history of GTN [79–
82].
12. Patients withPersistentLow hCG Levels
In a subset of patients with GTN, the hCG may plateau
at very low levels for several weeks or months. Metastatic
workup in these patients is often negative, and they are
characterized as having quiescent GTN. Interestingly, the
hCG form that is primarily present in these cases is the
nonhyperglycosylated form [82–85]. Provided their hCG
remains stable, these patients do not require any additional
chemotherapy and are generally chemoresistant. However,
sustained hCG followup is essential as the hCG values may
begin to rise in 6–10% of women with quiescent GTN after
a prolonged period of stability. When the hCG elevates, a
higher percentage of the hCG becomes hyperglycosylated
and this is indicative of disease recurrence, at which point
chemotherapy should be instituted.
An intriguing subset of women may present with ele-
vated hCG levels but without a clear antecedent pregnancy
and without a progressive rise in their hCG value. This
phenomenon may be due to circulating heterophilic hCG
antibodies and is termed phantom hCG or phantom GTN
[79]. Negative urine hCG levels will distinguish false positive
p h a n t o ms e r u mh C Gf r o mt r u ep o s i t i v es e r u mh C Ga n dwi l l
conﬁrm the diagnosis of phantom GTN.
In some instances, the hCG assays may have cross-
reactivity with luteinizing hormone (LH), which can lead
to false positive results if the patient’s LH levels are ele-
vated. This is particularly relevant in women with ovarian
impairment secondary to combination chemotherapy or to
peri- or postmenopausal status. It is, therefore, advisable to
treat women receiving combination chemotherapy with the
oral contraceptive pill to suppress LH levels and avoid false
positive hCG results.
Furthermore, peri- and postmenopausal women may
have persistent low levels of hCG that is pituitary in origin.
Pituitary hCG is physiologically produced with increasing
menopausal production of luteinizing hormone, owing to
the decreased production of estrogen and the suppression
of progesterone [86, 87]. To distinguish this phenomenon
from hCG secondary to trophoblastic disease, women can be
treated with estrogen, which would suppress pituitary hCG
but would not alter GTN produced hCG.
13. RecurrentGTN
Women with history of GTN have a potential risk of disease
recurrence that is largely dependent on their initial stage.
Mutch et al. reported recurrence rates of 2% in patients with
nonmetastatic GTN, 4% in patients with low-risk, metastatic
GTN, and 13% in patients with high-risk, metastatic disease
[88].AttheNETDC,thereportedrecurrencerateswere2.9%
in patients with stage I disease, 8.3% in stage II, 4.2% in
stage III, and 9.1% in patients with stage IV GTN [89]. The
mean time at our center from the last undetectable hCG level
to documented recurrence was 6 months, irrespective of the
FIGO stage. Similarly, Ngan et al. reported that the median
recurrence time in women from Hong Kong with GTN was
6.5 months [90]. The risk of recurrence increased in patients
withlargeinitialtumorburdenandinpatientswhodefaulted
on potential treatment or who did not comply with followup
[90].
Fortunately, recurrent GTN is often curable. At the
NETDC, all patients with recurrent stage I, II, and III disease
were cured with chemotherapy. Two patients with recurrent
stage IV GTN succumbed to their disease and the remainder
of patients with recurrent stage IV GTN were ultimately
cured using intensive combination chemotherapy.
14. SubsequentPregnancies
After a patient experiences a molar pregnancy, her risk of
developing a subsequent molar pregnancy increases from a
baseline of 1/1000 to 1/100 [91]. It is, therefore, prudent
to obtain a serum hCG value and a pelvic ultrasound
early in the ﬁrst trimester of all subsequent pregnancies to
conﬁrm normal gestational development. In addition, hCG
levels should be measured 6 weeks after the completion of
each future pregnancy to exclude the presence of occult
trophoblastic disease.
The secondary infertility rate in women who were previ-
ously treated with chemotherapy for GTN is approximately
7% [92–99]. As such, the majority of women who are inter-
ested in conceiving after completion of GTN treatment will
be successful. The reproductive outcomes of 2,657 women
who were previously treated using chemotherapy for GTN at
9 centers, including the NETDC, were described in multiple
reports [92–99]. The majority of pregnancies achieved live
births; with 2,038 (76.7%) term births, 71 (5.3%) premature
births, 34 (1.3%) stillbirths and 378 (14.2%) spontaneous
miscarriages. Notably, 37 infants (1.8%) were born with
congenital malformations. This rate is comparable to the
general population and is reassuring that chemotherapeutic
regimens used in the treatment of GTN do not appear
to increase the rate of congenital anomalies in subsequent
pregnancies. Furthermore, Woolas et al. noted no diﬀerences
in conception rates or pregnancy outcomes between women
treated with single-agent MTX and those receiving combina-
tion chemotherapy [99].
At the NETDC, we recommend a followup period of 12
months for women with stage I, II, and III GTN and of
24 months for stage IV disease, during which the patient
is advised not to conceive. This is not only crucial to the8 Chemotherapy Research and Practice
appropriate interpretation of the hCG levels but also to the
well-being of the subsequent gestation. Matsui et al. reported
that pregnancies within 6 months of treatment completion
are at increased risk for spontaneous miscarriages, stillbirths,
and repeat moles [100].
15. Novel Treatments inPatientswith
EMACOResistance
Patients with disease resistant to current chemotherapeutic
protocols pose a signiﬁcant treatment challenge and eﬀorts
continue to identify new eﬀective agents to treat resistant
GTN. Osborne et al. described a novel, 3-drug doublet
regimen, consisting of paclitaxel, etoposide, and cisplatin
(TP/TE) that induced complete remission in two patients
with relapsed high-risk GTN [101]. Wang et al. further
studied this regimen in 16 patients with chemoresistant dis-
ease, including 6 patients previously treated with platinum-
based chemotherapy. Three of 16 patients (19%) achieved
a complete response and 5 of 16 (31%) a partial response.
In addition, the TP/TE protocol was well tolerated, with
only one patient discontinuing therapy because of toxic
eﬀects. Thus, the TP/TE regimen appears eﬀective in treating
refractory GTN and may be better tolerated by patients than
EMAEP [102]. Consequently, the International Society for
the Study of Trophoblastic Disease (ISSTD) has proposed a
randomized trial comparing TP/TE to EMAEP in patients
with recurrent GTN after treatment with EMACO.
Wan et al. described 100% eﬃcacy of a ﬂoxuridine-
(FUDR-) containing treatment when given to 21 patients
withdrug-resistantGTN[103].Matsuietal.foundthat5-FU
in combination with ACT-D may be used as salvage therapy
and induced complete remission in 9 of 11 (82%) patients
with drug-resistant GTN [104]. To treat drug-resistant GTN,
acombinationofcisplatin,vinblastine,andbleomycin(PVB)
has been studied by Gordon et al., DuBeshter et al. and Azab
et al. who reported that complete remission was achieved
in 2 of 11 patients (18%), 4 of 7 patients (57%), and 5
of 8 patients (62%), respectively [105–107]. Ifosfamide and
paclitaxel are sometimes used to treat GTN; however, further
studies are needed to conﬁrm their potential role as either
primary or secondary treatment agents [108, 109].
An interesting potential treatment avenue for women
with refractory GTN is the use of autologous bone marrow
transplantation or stem-cell support concurrent with high-
dose chemotherapy. Although complete remission has been
reported in selected cases, the proper role of these measures
in the treatment of GTN is yet to be deﬁned [110, 111].
16. Conclusion
Signiﬁcant progress has been made over the past decades
in the diagnosis and management of women with GTN.
GTN is a highly curable disease that can be eﬀectively man-
aged with single- or multiagent chemotherapy. Nonetheless,
some women succumb from GTN primarily due to late
presentation, delayed diagnosis of primary or recurrent
disease,ordrugresistance.Therefore,educatingprimarycare
physicians and gynecologists about the signs and symptoms
of GTN is essential in decreasing adverse outcomes related
to this disease. In addition, careful followup of all women
with GTN is important to ensure that recurrence is detected
promptly, at a time when it is curable. Moreover, the
discovery of novel therapeutics may decrease drug toxicity,
enhance treatment eﬃcacy, and improve the management of
women with chemoresistant disease.
Lastly, it is well established that the diagnosis of GTN
may have a signiﬁcant emotional impact on the patient
and her family [111, 112]. Therefore, it is vital that these
women are followed by a multidisciplinary team, where the
psychological impact of this diagnosis and its treatment can
beaddressed.Thisapproachwillensureoptimal,holisticcare
for women with GTN.
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